Skip to content

Optimization of light, moderate to severe atopic dermatitis treatment strategies of the stabilization period: multicenter, open, randomized controlled study

Optimization of light, moderate to severe atopic dermatitis treatment strategies of the stabilization period: multicenter, open, randomized controlled study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002591
Enrollment
Unknown
Registered
2012-09-16
Start date
2012-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

test group:Tacrolimus ointment+Emollient Bathing + moisturizers
test group:Tacrolimus ointment+Emollient Bathing
test group:Tacrolimus ointment+Ordinary Bathing + moisturizer
test group:Tacrolimus ointment+Ordinary Bathing
test group:Fluticasone propionate cream+Emollient Bathing + moisturizers
test group:Fluticasone propionate cream+Emollient Bathing
test group:Fluticasone propionate cream+Ordinary Bathing + moisturizers
test group:Fluticasone propionate cream+Ordinary Bathing+ moisturizers

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) meet Williams diagnostic criteria, and with SCORAD score in 50 minutes or less, mild (<25) to moderate (25-50) or moderate the emphasis degrees (50-70), atopic dermatitis; (2) the age of 2-70 years of age, both men and women; (3) referral to the hospital when atopic dermatitis recurrence within 2 days; (4) signed informed consent.

Exclusion criteria

Exclusion criteria: (1) a known allergy to the study drug or its ingredients; (2) atopic dermatitis lesions region have serious infections of the skin; (3) severe liver and kidney diseases, blood diseases, autoimmune diseases, chronic severe infections, diabetes, mental illness, drug and alcohol abuse, etc.; (4) malignancy or other serious diseases that may affect the right to assess the efficacy; (5) topical corticosteroids or other immunosuppressant withdrawal time of less than one week; system with corticosteroids and other immunosuppressive agents (triptolide) withdrawal time of less than two weeks; (6) a month to participate in other clinical studies; (7) The researchers recogniz the person who not eligible for inclusion.

Design outcomes

Primary

MeasureTime frame
lesion chang;

Countries

China

Contacts

Public ContactXing-hua Gao
gaobarry@hotmail.com+86 13940152467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026